Mahady, Redmond move up at Wyeth

Share this article:
Wyeth named Joe Mahady president, Wyeth Pharmaceuticals and SVP, Wyeth.

In February, Mahady was named president, global business for the company's pharmaceuticals division, with responsibility for all worldwide commercial business. Prior to that, he was president, Americas and global business, in which role he presided over steep cuts in the company's US primary care sales force, supplemented by the hiring of flex-time reps. He joined the company in 1979 as a pharmacist with its regulatory affairs division.

Also moving up are Wyeth BioPharma head Cavan Redmond, who becomes president, Wyeth Consumer Healthcare, and Richard DeLuca, who becomes president, Fort Dodge Animal Health.

They will assume their new roles Jan. 1, the day Bernard Poussot takes the reins from CEO Bob Essner, who is retiring.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.